Oncotelic Therapeutics, Inc. (OTCQB: OTLC), along with its wholly owned subsidiary Pet2DAO, Inc., announced that its PDAOAI artificial intelligence-powered drug discovery platform is inviting scientists, AI developers and biotech founders to participate in BIO REBOOT. According to the announcement, participants can bring research questions, technical expertise and drug discovery ideas to the PDAOAI community, with selected projects potentially considered for startup funding and Oncotelic support covering validation, formulation, regulatory planning and clinical development. The initiative aims to foster collaboration between AI experts and life sciences researchers, potentially accelerating the translation of computational insights into viable therapeutic candidates.
The company also announced two PDAOAI keynote presentations at the 10th International Conference on Drug Discovery & Lead Optimization, taking place Oct. 7-9, 2026, in Burlingame, California. Chief Business Officer Saran Saund will present a hepatocellular carcinoma case study illustrating how Partitioned Literature Aggregation generated a candidate four-gene signature. Product Manager Scott Myers will discuss AI search aggregation for biomedical knowledge discovery in drug development. These presentations underscore the growing role of AI in identifying novel drug targets and streamlining discovery workflows, which could lead to more efficient development of therapies for cancers with substantial unmet needs.
Oncotelic Therapeutics, Inc. develops oncology and immunotherapy products, with a focus on cancers with substantial unmet needs and rare pediatric indications. The company also develops the PDAOAI platform to support its work in drug discovery and development. By opening BIO REBOOT to external participants, Oncotelic is positioning itself at the intersection of AI and biotechnology, potentially creating a pipeline of innovative projects that could benefit from its expertise and resources. For investors and industry observers, this move signals a strategic effort to leverage AI for drug discovery, which may enhance the company's research capabilities and lead to new intellectual property.
The implications extend beyond Oncotelic. The BIO REBOOT initiative and the conference presentations highlight how AI is transforming drug discovery, from literature aggregation to target identification. If successful, such approaches could reduce the time and cost of bringing new therapies to market, ultimately benefiting patients. For the biotech sector, Oncotelic's open invitation may encourage more cross-disciplinary collaboration, driving innovation. The latest news and updates relating to OTLC are available in the company's newsroom at https://ibn.fm/OTLC. To view the full press release, visit https://ibn.fm/dxB7y.
BioMedWire is a specialized communications platform with a focus on the latest developments in the Biotechnology, Biomedical Sciences and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries. The platform also provides article and editorial syndication to 5,000+ outlets, enhanced press release enhancement to ensure maximum impact, social media distribution via IBN to millions of social media followers, and a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BioMedWire is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. For more information, please visit www.BioMedWire.com. Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer.
